← Eichor
Condition: Relapsed Refractory Multiple Myeloma Rrmm Synced from ClinicalTrials.gov · July 28, 2026

Recruiting studies: Relapsed Refractory Multiple Myeloma Rrmm

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

A Study of Clinical Outcomes in Patients With Relapsed/Refractory Multiple Myeloma (RRMM) Treated With T-cell Redirector
Phase N/A · 68 location(s) · Janssen-Cilag Ltd. · NCT06285318A Study to Examine the Effects of Novel Therapy Linvoseltamab in Combination With Other Cancer Treatments for Adult Part
Phase 1 · 42 location(s) · Regeneron Pharmaceuticals · NCT05137054A Study to Evaluate Mezigdomide, Bortezomib and Dexamethasone (MEZIVd) Versus Pomalidomide, Bortezomib and Dexamethasone
Phase 3 · 266 location(s) · Celgene · NCT05519085A Study to Investigate Subcutaneous Isatuximab in Combination With Weekly Carfilzomib and Dexamethasone in Adult Partici
Phase 2 · 34 location(s) · Sanofi · NCT06356571Quality of Life and Treatment Outcomes in RRMM Patients Receiving Advanced vs. Conventional Immunotherapies
Phase N/A · 1 location(s) · Sung-Soo Park · NCT07051850A Study of OL-101 Injection in Patients with Relapsed or Refractory Multiple Myeloma (RRMM)
Phase 1 · 3 location(s) · Zhejiang University · NCT06644118Study Assessing Activity of Intravenous (IV) Etentamig Monotherapy Versus Standard Available Therapies in Adult Particip
Phase 3 · 166 location(s) · AbbVie · NCT06158841A Study to Evaluate RO7851624 in Participants With Relapsed/Refractory Multiple Myeloma (RRMM)
Phase 1 · 1 location(s) · Genentech, Inc. · NCT07558915A Study of Venetoclax in Combination With Isatuximab and Dexamethasone for Relapsed/Refractory Multiple Myeloma
Phase 2 · 2 location(s) · Oncotherapeutics · NCT06115135A Phase 2 Study of Radiotherapy-induced Immune Priming to Enhance Elranatamab (Elra) in Relapsed Refractory Multiple Mye
Phase 2 · 1 location(s) · M.D. Anderson Cancer Center · NCT07382739HCMT/MM2401: Ph2 Study of Selinexor + Bispecific Antibody for RRMM
Phase 2 · 1 location(s) · Duke University · NCT06822972Mezigdomide and Talquetamab in Relapsed and Refractory Multiple Myeloma
Phase 1 · 3 location(s) · Massachusetts General Hospital · NCT07032714Study of Arlocabtagene Autoleucel (BMS-986393) a GPRC5D-directed CAR T Cell Therapy in Adult Participants With Relapsed
Phase 2 · 52 location(s) · Juno Therapeutics, Inc., a Bristol-Myers Squibb Company · NCT06297226SX-682 in Combination With Carfilzomib, Daratumumab-Hyaluronidase, and Dexamethasone in Patients With Relapsed or Refrac
Phase 1 · 1 location(s) · Roswell Park Cancer Institute · NCT06622005Dual-target BCMA-GPRC5D CAR-T Cell Therapy for RR/MM With Extramedullary Infiltration
Phase 1 · 1 location(s) · Beijing GoBroad Hospital · NCT07003568A Trial to Study if REGN17372 in Combination With Linvoseltamab is Tolerable for Adult Participants With Relapsed/Refrac
Phase 1/Phase 2 · 5 location(s) · Regeneron Pharmaceuticals · NCT07455851A Study to Compare the Efficacy and Safety of BMS-986393 Versus Standard Regimens in Adult Participants With Relapsed or
Phase 3 · 141 location(s) · Juno Therapeutics, Inc., a Bristol-Myers Squibb Company · NCT06615479A Study to Compare Linvoseltamab Monotherapy and Linvoseltamab + Carfilzomib Combination Therapy With Standard-of-Care C
Phase 3 · 20 location(s) · Regeneron Pharmaceuticals · NCT07222761Dual-target BCMA-CD19 CAR-T Cell Therapy for RR/MM With Extramedullary Infiltration
Phase 1 · 1 location(s) · Beijing GoBroad Hospital · NCT07003555Mezigdomide and Elranatamab for Relapsed and/or Refractory Multiple Myeloma
Phase 1/Phase 2 · 7 location(s) · YOUNGIL KOH · NCT06645678Intravenous Autologous CD19 CAR-T Cells for R/ R MM, B-ALL, and B-Cell Lymphoma
NA · 1 location(s) · Anhui Provincial Hospital · NCT06961669GR1803 Injection in Patients With RRMM
Phase 2 · 1 location(s) · Genrix (Shanghai) Biopharmaceutical Co., Ltd. · NCT06952075Isatuximab in Combination With Novel Agents in RRMM - Master Protocol
Phase 1/Phase 2 · 26 location(s) · Sanofi · NCT0464300218F-Fluciclovine PET/CT in Multiple Myeloma
Phase 2 · 1 location(s) · National Cancer Institute (NCI) · NCT06103838Phase II Trials of Letermovir Prophylaxis in Patients With RRMM Undergoing Elranatamab Therapy
Phase 2 · 1 location(s) · Seoul National University Hospital · NCT06920251A Study of JNJ-79635322 in Participants With Relapsed or Refractory Multiple Myeloma
Phase 2 · 69 location(s) · Janssen Research & Development, LLC · NCT07266441ELISA in Relapsed/Refractory MM
Phase 2 · 3 location(s) · Massachusetts General Hospital · NCT06832865A Multicenter, Randomized, Open-label, Parallel-group, Controlled, Superiority Phase III Clinical Study Comparing the Ef
Phase 3 · 1 location(s) · Shandong New Time Pharmaceutical Co., LTD · NCT07579234A Study to Learn About the Effects of the Combination of Elranatamab (PF-06863135) and Iberdomide in Patients With Relap
Phase 1 · 43 location(s) · Pfizer · NCT06215118Elotuzumab + Iberdomide + Dexamethasone Post Ide-Cel in RRMM
Phase 1/Phase 2 · 3 location(s) · Omar Nadeem, MD · NCT06518551
Look up another condition
Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.